Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Seres Therapeutics, Inc. - Common Stock
(NQ:
MCRB
)
7.055
+0.100 (+1.44%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Seres Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials
June 01, 2021
The FDA has signed off Seres Therapeutics Inc's (NASDAQ: MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial. SER-155 is a...
Via
Benzinga
Exposures
Product Safety
Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
June 01, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at Upcoming Virtual Investor Conferences
May 25, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021
May 21, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
May 20, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 19, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
May 12, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 11, 2021
Gainers Applied DNA Sciences (NASDAQ:APDN) shares rose 27.71% to $7.42 during Tuesday's regular session. Trading volume for Applied DNA Sciences's stock is 7.2...
Via
Benzinga
Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting
May 11, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
May 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Seres Therapeutics: Q1 Earnings Insights
May 04, 2021
Shares of Seres Therapeutics (NASDAQ:MCRB) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 39.29% year over year to ($0...
Via
Benzinga
Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
May 04, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021
April 28, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit
April 15, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For May 4, 2021
May 04, 2021
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.